Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be more than 1 month old.~2. Have a history of culture positive fungal corneal ulcer, that began within 14 days of presentation to the study center characterized by either a stromal defect with infiltrate or exudate, or a positive fungal stain on smear. Other clinical criteria to suspect fungal ulcers include firm (sometimes dry) elevated slough, hyphate lines extending beyond the ulcer edge into normal cornea, endothelial plaque, history of organic material striking the eye, intense inflammation of the cornea and anterior chamber, immune ring, Descemet's folds, multifocal granular (or feathery) grey-white satellite stromal infiltrates. A hypopyon may be present. The diameter of the ulcer will be between 1 mm and 6 mm, as long as there is no scleral involvement.~3. It is acceptable to enroll a subject who has received a graft, provided the graft meets the following requirements:~   1. The central ulcer is well within the donor cornea.~  2. There is no suture abscess.~  3. The graft has not previously failed.~4. The subject should not have a foreign body present on or in the cornea or eye. A subject can be enrolled after the foreign body is totally removed and the other enrollment criteria are met.~Exclusion Criteria:~1. The initial culture fails to show the presence of fungi.~2. The patient has a history of allergy to povidone-iodine, iodine, or natamycin.~3. The cornea or sclera has been perforated or perforation is impending.~4. The unaffected eye is legally blind.~5. Dacrocystitis is present.~6. Neurotrophic keratitis, exposure keratitis or keratitis sicca is present.~7. Prescribed topical or systemic steroids or other immunosuppressants are being used, unless discontinued before randomization.~8. The patient is known to be HIV positive.~9. The infiltrate extends into the posterior one-third of the stroma.~10. The initial culture shows significant growth of bacteria (\>10 colonies).~11. Any topical antifungal agent has been used within the past week.~12. Both eyes are infected.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I: (Type: EXPERIMENTAL): povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
- II (Type: ACTIVE_COMPARATOR): natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).